Dr Jennifer Smith is Deputy Director of the ICCB-Longwood Screening Facility and Lecturer in the Microbiology and Immunobiology Department at Harvard Medical School. She is a broadly trained molecular biologist with expertise in virology, assay development, high throughput screening and data analysis strategies. Jen obtained her Ph.D. from the University of Minnesota in the Microbiology, Immunology and Cancer Biology Program where she studied oncolytic reovirus and cellular translational inhibition. She carried out her postdoctoral research in Peter Howley’s laboratory at Harvard Medical School, focusing on oncogenic papillomaviruses. In 2011, Jen joined the ICCB-Longwood Screening Facility, which is one of the oldest academic high throughput screening centres.
Bartek Rajwa is an Associate Research Professor of Computational Life Sciences in the Bindley Bioscience Center at Purdue University where he is conducting studies on the technology of high-throughput cytometry, high-content imaging, biological pattern recognition, and applications of statistical machine learning in cell biology, cancer research, agriculture, and bioengineering. Dr. Rajwa is particularly interested in integrating biological data from a variety of linked single-cell technologies from flow cytometry through biological imaging to proteomics and functional genomics. His studies employ mathematical models to decipher and interpret complex phenotypic patterns observed via quantitative cell analysis. Working with collaborators Dr. Rajwa has developed automated pipelines for clinical flow cytometry analysis, biothreat identification (biosurveillance) algorithms, and spectral information processing approaches for fluorescence and Raman cytometry and microscopy. He has also been a co-inventor of multispectral flow cytometry (licensed and commercialized by Sony Biotechnology, Inc.), and elastic-light-scatter microorganism identification technology. Since 2009 Dr. Rajwa has been a member of the Editorial Board of Cytometry Part A (the official journal of the International Society for Advancement of Cytometry). Since 2013 he has been working as an Associate Editor responsible for the computational cytometry and imaging content of this journal. In 2017 Dr. Rajwa has been elected to the Board of Directors of the Society for Biomolecular Imaging and Informatics.
Shannon Mumenthaler, Ph.D., is an Assistant Professor of Medicine at the University of Southern California. She is also the Director of the Stephenson Family Personalized Medicine Center of USC. Dr. Mumenthaler completed her Bachelors of Science in Genetics at UC Davis. She then went on to earn a doctoral degree in Cellular and Molecular Pathology at UCLA and carried out her postdoctoral training at Cedars-Sinai Medical Center and USC. Shannon has over 10 years of experience working with various tumor models and cell biology techniques. Her research passion is taking a multidisciplinary approach to examine the impact of the tumor microenvironment on treatment response. She is developing more physiologically-relevant model systems that capture the microenvironmental context of a tumor and coupling these preclinical models with quantitative microscopy-based imaging pipelines to provide deeper insights into the evolving tumor.
Dr Myles Fennell has been a Senior Research Scientist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY since 2013. He is currently responsible for developing and running RNAi, CRISPR and small molecule screens in both arrayed and pooled formats using a variety of technologies including high-content screening, FACS and next-generation sequencing. After receiving his PhD from the University of Edinburgh, he went on to hold positions at Wyeth Neuroscience, Bristol Myers-Squibb and Gigacyte. His experience in high-content screening has been pivotal in developing novel image based screens for researchers at MSKCC and other institutions.
Dr Jonathan Chesnut received a PhD in Cell and Molecular Biology from UC Davis (1994) and did postdoctoral studies at the University of Colorado in recombinant antibody technology development (1994-95). Prior to graduate school, he was employed at the Salk Institute (1983-84) and Hybritech Inc. in La Jolla, CA (1984-88). After his post doctoral research at Colorado he joined Invitrogen as a research scientist (1995). Since then he has led the development of various prokaryotic and mammalian cell cloning and expression systems. He has led groups focused on development of TOPO and Gateway cloning as well as the human embryonic cell engineering technologies. He now leads the Synthetic Biology Research and Development Team in the Life Sciences Solutions Group of Thermo Fisher Scientific in Carlsbad, CA. His group is focused on developing tools for the entire Synthetic Biology and Cell Engineering workflow, specifically Bioinformatics, Genome Editing, and Cellular Analytics.
David M. Evans, Ph.D, Co-founder and CSO, Sirnaomics Inc. has over 20 years experience in drug target and small molecule discovery for oncology, infectious diseases and CNS therapeutics. Dr. Evans has been a pioneer in target/drug discovery technologies including high throughput gene silencing using RNAi. Before joining Sirnaomics, Inc. David served as Sr. Director, RNAi Discovery and Therapeutic Services group, for Dharmacon (Thermo Fisher Scientific (TFS), Lafayette, CO); Head of Drug Discovery, Cancer Drug Development Lab, Translational Genomics Research Institute (TGEN), Gaithersburg, MD; Director, Drug Discovery Psychiatric Genomics Inc., Gaithersburg, MD; and Head, High Throughput Screening for Serono Pharmaceuticals, Boston, MA. Prior to this David was with Millennium Pharmaceuticals, Cambridge, MA. Dr. Evans is the inventor on a number of issued and pending patents, and has been an invited speaker for many international professional conferences and webinars on siRNA screening and drug discovery. He received his BSc (1983) and PhD (1987) from Imperial College, London and has published a number of peer reviewed papers and review articles.
Reed Hickey is the Director of Technical Sales Support for Twist Bioscience, responsible for building an exceptional global technical support organization. Prior to his role in technical sales support, he served as Director of Product Management. Prior to Twist Bioscience, he served in a variety of escalating positions over more than a decade at Invitrogen, with his positions spanning strategic planning to product management to scientist supporting both operations and services. Also during his time at Invitrogen, he was responsible for launching the second generation of genome editing technologies. Reed holds a B.S. in Molecular Biology from University of California San Diego and an M.B.A. from California State San Marcos. Prior to graduate school, he conducted academic research focused on molecular cardiology at both Yale University and University of California San Diego.